| LDR | | 05134cmm u2200721 i 4500 |
| 001 | | 000000326853 |
| 003 | | OCoLC |
| 005 | | 20240307134416 |
| 006 | | m d |
| 007 | | cr cn||||||||| |
| 008 | | 220405s2022 dcua ob 000 0 eng |
| 010 | |
▼a 2021950193 |
| 016 | 7 |
▼a 9918382878206676
▼2 DNLM |
| 019 | |
▼a 1295276451 |
| 020 | |
▼a 9780309087827
▼q (electronic bk.) |
| 020 | |
▼a 0309087821
▼q (electronic bk.) |
| 020 | |
▼z 9780309087810 |
| 020 | |
▼z 0309087813 |
| 035 | |
▼a 3165656
▼b (N$T) |
| 035 | |
▼a (OCoLC)1296425995
▼z (OCoLC)1295276451 |
| 040 | |
▼a NLM
▼b eng
▼e rda
▼c NLM
▼d N$T
▼d TXM
▼d EBLCP
▼d OCLCQ
▼d OCLCO
▼d 248032 |
| 042 | |
▼a pcc |
| 049 | |
▼a MAIN |
| 050 | 4 |
▼a RA644.C67
▼b V33 2022 |
| 060 | 00 |
▼a WC 515 |
| 082 | 04 |
▼a 625.7 s 625.8/5 |
| 245 | 00 |
▼a Vaccine research and development to advance pandemic and seasonal influenza preparedness and response :
▼b lessons from COVID-19 /
▼c Hoda Soltani, Kanta Subbarao, Enriqueta Bond editors ; Committee on Vaccine Research and Development Recommendations for Advancing Pandemic and Seasonal Influenza Preparedness and Response. Board on Global Health, Health and Medicine Division. |
| 264 | 1 |
▼a Washington, DC :
▼b National Academies Press,
▼c [2022] |
| 300 | |
▼a 1 online resource (1 PDF file (xxiii, 153 pages)) :
▼b illustrations, color maps, charts. |
| 336 | |
▼a text
▼b txt
▼2 rdacontent |
| 337 | |
▼a computer
▼b c
▼2 rdamedia |
| 338 | |
▼a online resource
▼b cr
▼2 rdacarrier |
| 490 | 1 |
▼a Consensus study report |
| 504 | |
▼a Includes bibliographical references. |
| 505 | 0 |
▼a Front Matter -- Summary -- 1. Introduction -- 2. Basic and Translational Science -- 3. Clinical Science -- 4. Manufacturing Science -- 5. Regulatory Science -- 6. A Blueprint for Action -- Appendix A: Committee Biographies -- Appendix B: Disclosure of Unavoidable Conflict of Interest -- Appendix C: Staff and Consultant Biographies -- Appendix D: Public Meeting Agendas. |
| 520 | 3 |
▼a The global response to COVID-19 has demonstrated the importance of vigilance and preparedness for infectious diseases, particularly influenza. There is a need for more effective influenza vaccines and modern manufacturing technologies that are adaptable and scalable to meet demand during a pandemic. The rapid development of COVID-19 vaccines has demonstrated what is possible with extensive data sharing, researchers who have the necessary resources and novel technologies to conduct and apply their research, rolling review by regulators, and public-private partnerships. As demonstrated throughout the response to COVID-19, the process of research and development of novel vaccines can be significantly optimized when stakeholders are provided with the resources and technologies needed to support their response. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response focuses on how to leverage the knowledge gained from the COVID-19 pandemic to optimize vaccine research and development (R&D) to support the prevention and control of seasonal and pandemic influenza. The committee's findings address four dimensions of vaccine R&D: (1) basic and translational science, (2) clinical science, (3) manufacturing science, and (4) regulatory science. |
| 536 | |
▼a This activity was supported by a contract between the National Academy of Sciences and the Office of Global Affairs with the U.S. Department of Health and Human Services. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. |
| 588 | |
▼a Description based on online resource; title from PDF title page (viewed July 5, 2022). |
| 590 | |
▼a WorldCat record variable field(s) change: 650 |
| 650 | 0 |
▼a COVID-19 (Disease) |
| 650 | 0 |
▼a Influenza vaccines. |
| 650 | 0 |
▼a COVID-19 vaccines. |
| 650 | 12 |
▼a Influenza, Human
▼x prevention & control |
| 650 | 12 |
▼a Influenza Vaccines |
| 650 | 22 |
▼a COVID-19
▼x prevention & control |
| 650 | 22 |
▼a COVID-19 Vaccines |
| 650 | 22 |
▼a Vaccine Development |
| 650 | 2 |
▼a COVID-19 |
| 650 | 6 |
▼a COVID-19. |
| 650 | 6 |
▼a Vaccins antigrippaux. |
| 650 | 6 |
▼a Vaccins contre la COVID-19. |
| 650 | 7 |
▼a COVID-19 (Disease)
▼2 fast |
| 650 | 7 |
▼a Influenza vaccines
▼2 fast |
| 651 | 2 |
▼a United States |
| 700 | 1 |
▼a Soltani, Hoda,
▼e editor. |
| 700 | 1 |
▼a Subbarao, Kanta,
▼e editor. |
| 700 | 1 |
▼a Bond, Enriqueta C.,
▼e editor. |
| 710 | 2 |
▼a National Academies of Sciences, Engineering, and Medicine (U.S.).
▼b Committee on Vaccine Research and Development Recommendations for Advancing Pandemic and Seasonal Influenza Preparedness and Response,
▼e issuing body. |
| 776 | 08 |
▼i Print version:
▼a Medicine, National Academy of
▼t Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response
▼d Washington, D.C. : National Academies Press,c2022
▼z 9780309087810 |
| 830 | 0 |
▼a Consensus study report. |
| 856 | 40 |
▼3 EBSCOhost
▼u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3165656 |
| 938 | |
▼a EBSCOhost
▼b EBSC
▼n 3165656 |
| 990 | |
▼a 관리자 |
| 994 | |
▼a 92
▼b N$T |